Australian tafenoquine information

June 2019
GSK Group

Tafenoquine is indicated for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for the acute P. vivax infection.